Invivyd (IVVD)

• Market cap: $48.7M
• 1 day: 0.27%
• 5 days: 4.49%
• 1 month: -13.50%
• 3 months: -60.05%
• 6 months: -66.60%
• Year to date: -15.10%
• 1 year: -90.94%
• 5 years: -98.05%
• 10 years: -98.05%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Employees: 95

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

4.03% less ownership

Funds ownership: 63.9% [Q2] → 59.87% (-4.03%) [Q3]

5% less funds holding

Funds holding: 80 [Q2] → 76 (-4) [Q3]

12% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 17

13% less capital invested

Capital invested by funds: $83.8M [Q2] → $72.9M (-$10.9M) [Q3]

29% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 24

50% less call options, than puts

Call options by funds: $2K | Put options by funds: $4K

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3.55 771% upside
• Avg. target: $7.89 1,836% upside
• High target: $10 2,354% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 39% 1-year accuracy 76 / 193 met price target	2,109% upside $9	Buy Maintained	10 Jan 2025
Morgan Stanley Maxwell Skor 0% 1-year accuracy 0 / 2 met price target	771% upside $3.55	Overweight Maintained	20 Nov 2024
HC Wainwright & Co. Patrick Trucchio 29% 1-year accuracy 45 / 156 met price target	2,354% upside $10	Buy Maintained	20 Nov 2024
EF Hutton Jason Kolbert 39% 1-year accuracy 76 / 193 met price target	2,109% upside $9	Buy Initiated	30 Oct 2024